These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8968363)

  • 41. Inhibition of regrowth of prostatic glandular cells by epristeride.
    Qian LH; Wang XL; Tu ZH
    Acta Pharmacol Sin; 2001 Sep; 22(9):847-50. PubMed ID: 11749869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiaggregatory activity of 8-epi-prostaglandin F2 alpha and other F-series prostanoids and their binding to thromboxane A2/prostaglandin H2 receptors in human platelets.
    Yin K; Halushka PV; Yan YT; Wong PY
    J Pharmacol Exp Ther; 1994 Sep; 270(3):1192-6. PubMed ID: 7932171
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacologic characterization of human and canine thromboxane A2/prostaglandin H2 receptors in platelets and blood vessels: evidence for different receptors.
    Mais DE; Saussy DL; Chaikhouni A; Kochel PJ; Knapp DR; Hamanaka N; Halushka PV
    J Pharmacol Exp Ther; 1985 May; 233(2):418-24. PubMed ID: 2987481
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Epristeride is a selective and specific uncompetitive inhibitor of human steroid 5 alpha-reductase isoform 2.
    Levy MA; Brandt M; Sheedy KM; Dinh JT; Holt DA; Garrison LM; Bergsma DJ; Metcalf BW
    J Steroid Biochem Mol Biol; 1994 Feb; 48(2-3):197-206. PubMed ID: 8142295
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Decrease in vascular TxA2 receptors in a subgroup of rabbits unresponsive to a TxA2 mimetic.
    Buzzard CJ; Pfister SL; Halushka PV; Campbell WB
    Am J Physiol; 1994 Jun; 266(6 Pt 2):H2320-6. PubMed ID: 8023992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of cultured rat prostatic epithelial cell growth by epristeride in vitro.
    Wu SF; Sun HZ; Tu ZH; Wu HY
    Acta Pharmacol Sin; 2001 Mar; 22(3):257-63. PubMed ID: 11742574
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro effects of epristeride on sperm in rats, dogs and man.
    Wu JH; Sun ZY; Cao L
    Arch Androl; 2006; 52(3):191-5. PubMed ID: 16574601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Homologous desensitization of human platelet thromboxane A2/prostaglandin H2 receptors.
    Okwu AK; Ullian ME; Halushka PV
    J Pharmacol Exp Ther; 1992 Jul; 262(1):238-45. PubMed ID: 1378092
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reversible long-term toxicity of epristeride in beagle dogs.
    Sun ZY; Feng J; Qi XD; Wu HY; Zheng WJ; Tu ZH
    Toxicol Appl Pharmacol; 1999 Jan; 154(2):145-52. PubMed ID: 9925798
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex.
    Ajayi AA; Fidelis P
    J Cardiovasc Pharmacol; 2006 Nov; 48(5):191-8. PubMed ID: 17110800
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Androgen regulation of thromboxane A2 receptors.
    Ajayi AA; Matsuda K; Schrör K; Masuda A; Mathur R; Halushka PV
    Adv Prostaglandin Thromboxane Leukot Res; 1995; 23():251-3. PubMed ID: 7732846
    [No Abstract]   [Full Text] [Related]  

  • 52. Growth factors downregulate vascular smooth muscle thromboxane receptors independent of cell growth.
    Dorn GW; Becker MW
    Am J Physiol; 1992 Apr; 262(4 Pt 1):C927-33. PubMed ID: 1533095
    [TBL] [Abstract][Full Text] [Related]  

  • 53. U-46619, a selective thromboxane A2 mimetic, inhibits the release of endogenous noradrenaline from the rat hippocampus in vitro.
    Nishihara M; Yokotani K; Inoue S; Osumi Y
    Jpn J Pharmacol; 2000 Mar; 82(3):226-31. PubMed ID: 10887953
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activation of thromboxane A2 receptors alters lipopolysaccharide-induced adherence of THP-1 cells.
    Wagner RS; Halushka PV; Cook JA
    Shock; 1996 Jan; 5(1):41-6. PubMed ID: 8821102
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The mechanism of epristeride against benign prostatic hyperplasia.
    Sun ZY; Wu HY; Wang MY; Tu ZH
    Eur J Pharmacol; 1999 Apr; 371(2-3):227-33. PubMed ID: 10357260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decrease in thromboxane A2 receptor expression by differentiation with dibutyryl cyclic AMP in 1321N1 human astrocytoma cells.
    Honma S; Nakahata N; Kobayashi H; Ikeda S; Takeda N; Ohizumi Y
    Prostaglandins Other Lipid Mediat; 1999 Aug; 58(1):51-62. PubMed ID: 10482287
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Thromboxane A2 receptor is highly expressed in mouse immature thymocytes and mediates DNA fragmentation and apoptosis.
    Ushikubi F; Aiba Y; Nakamura K; Namba T; Hirata M; Mazda O; Katsura Y; Narumiya S
    J Exp Med; 1993 Nov; 178(5):1825-30. PubMed ID: 8228829
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Normal-phase high-performance liquid chromatographic determination of epristeride, a prostatic steroid 5 alpha-reductase enzyme inhibitor, in human plasma.
    Boppana VK; Miller-Stein C; Rhodes GR
    J Chromatogr; 1993 Feb; 631(1-2):251-4. PubMed ID: 8450017
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Thromboxane receptor density is increased in human cardiovascular disease with evidence for inhibition at therapeutic concentrations by the AT(1) receptor antagonist losartan.
    Katugampola SD; Davenport AP
    Br J Pharmacol; 2001 Dec; 134(7):1385-92. PubMed ID: 11724743
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Regulation of the rat aortic smooth muscle cell thromboxane A2 receptor.
    Cockerham C; Webb ML; Hedberg SA; Runge MS
    Trans Assoc Am Physicians; 1991; 104():173-80. PubMed ID: 1845143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.